Prof. Dr. Daniel Krappmann

Head of Research Unit Signaling and Translation

+49 89 3187 3461 daniel.krappmann@helmholtz-muenchen.de

“My research is dedicated to decipher molecular machineries controlling immune activation and to translate this findings into the development of new therapies to fight immune diseases and cancer.”

He started his academic career as a PhD student and continued his studies on signal transduction in cancer cells as a postdoctoral fellow and junior group leader at the Max-Delbrück-Center (MDC) for Molecular Medicine in Berlin. His Research Unit at Helmholtz Munich is dedicated to study physiological and pathological signaling pathways in the immune system and in cancer.

The identification of the pro-proliferative and anti-apoptotic function of signaling networks in human tumor cells inspired his long-standing efforts to bridge the gap between basic science and clinical translation. He has been leading a successful drug discovery program and the pre-clinical development of new immune modulatory drugs. Candidate drugs from this program are currently tested in the clinic for their ability to boost our immune defence to fight cancer.

Immunology Oncology Cancer

Cell Signaling T cell Biology Target Identification Drug Discovery

since 2023

since 2013

since 2012

2005 - 2012

2002 - 2005

1997 - 2002

Delbrück Fellowship Award (MDC Berlin) 2002

Jones, A.N., C. Grass, I. Meininger, A. Geerlof, M. Klostermann, K. Zarnack, D. Krappmann, and M. Sattler

Modulation of pre-mRNA structure by hnRNP proteins regulates alternative splicing of MALT1.

O'Neill, T.J., T. Seeholzer, A. Gewies, T. Gehring, F. Giesert, I. Hamp, C. Grass, H. Schmidt, K. Kriegsmann, M.J. Tofaute, K. Demski, T. Poth, M. Rosenbaum, T. Schnalzger, J. Ruland, M. Gottlicher, M. Kriegsmann, R. Naumann, V. Heissmeyer, O. Plettenburg, W. Wurst, and D. Krappmann

TRAF6 prevents fatal inflammation by homeostatic suppression of MALT1 protease.

Kutukculer, N., T. Seeholzer, T.J. O'Neill, C. Grass, A. Aykut, N.E. Karaca, A. Durmaz, O. Cogulu, G. Aksu, T. Gehring, A. Gewies, and D. Krappmann

Human immune disorder associated with homozygous hypomorphic mutation affecting MALT1B splice variant.

Stangl, A., P.R. Elliott, A. Pinto-Fernandez, S. Bonham, L. Harrison, A. Schaub, K. Kutzner, K. Keusekotten, P.T. Pfluger, F. El Oualid, B.M. Kessler, D. Komander, and D. Krappmann

Regulation of the endosomal SNX27-retromer by OTULIN.

Meininger, I., R.A. Griesbach, D. Hu, T. Gehring, T. Seeholzer, A. Bertossi, J. Kranich, A. Oeckinghaus, A.C. Eitelhuber, U. Greczmiel, A. Gewies, M. Schmidt-Supprian, J. Ruland, T. Brocker, V. Heissmeyer, F. Heyd, and D. Krappmann

Alternative splicing of MALT1 controls signalling and activation of CD4(+) T cells.

Nagel, D., S. Spranger, M. Vincendeau, M. Grau, S. Raffegerst, B. Kloo, D. Hlahla, M. Neuenschwander, J. Peter von Kries, K. Hadian, B. Dorken, P. Lenz, G. Lenz, D.J. Schendel, and D. Krappmann

Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.